Question for the Pharma SavvyI know some of you are fairly insightful about this industry. This question is for you. Forget high hopes and theoretical future potential for a moment, because there are a lot of "ifs" and a lot of execution and delivery that hasn't happened yet, in the bigger picture right?
It seems that what we do have is some impressive technology and some very encouraging partial clinical trial data. And a whole bunch of very compelling pre-clinical data. I'm wondering if any of you have a feel for what the company could be worth right now? Not based on a bunch of maybes/ifs, but based on the current set of knowns and unknowns. And without BTD. Or is the company only a buyout candidate after BTD, because that effectively removes some of the unknowns? I'm wondering if this is why the market shuns this company, not enough officially endorsed progress (FDA)? Too high % chance of failure at this point?